- |||||||||| Lenocta (sodium stibogluconate) / VioQuest, Lamprene (clofazimine) / Novartis
Infectious skin diseases among global refugee and migrant population: A Systematic Review () - Feb 26, 2025 - Abstract #AAD2025AAD_3268;
Targeted dermatological interventions are crucial for refugee and migrant populations. Emphasizing timely diagnosis, access to care, and preventative measures can improve outcomes and guide evidence-based care for these patients.
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Journal: Comparative assessment of colorimetric assays in evaluating intracellular drug susceptibility of Leishmania tropica against conventional antileishmanial drugs. (Pubmed Central) - Feb 19, 2025
Intracellular drug susceptibility of CL isolates was subsequently assessed in a macrophage/amastigote model by infecting THP-1 macrophages with promastigotes from both reference and patient isolates, followed by treatment with MA, sodium stibogluconate (SSG), miltefosine (MTF), pentamidine (PMD), and amphotericin B (AmB)...Expanding the isolate set is necessary to further evaluate the predictive value of SbV (pentavalent antimonials) susceptibility for treatment outcomes. The identification of XTT as the most sensitive method for intracellular antileishmanial susceptibility testing is expected to aid in standardizing laboratory models and provide valuable insights for researchers and clinicians managing treatment-unresponsive CL cases.
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Journal: Cutaneous Leishmaniasis Masquerading as Diabetic Foot: A Call for Vigilance. (Pubmed Central) - Jan 13, 2025
The patient is currently under treatment with systemic sodium stibogluconate (pentostam)...They believed that biopsies are indispensable in the microbiology workup of specific pathogens such as mycobacteria, Leishmania, actinomycetes, Nocardia ssp., or molds (5). The present case highlights the importance of proper investigation of foot ulcer and the importance of considering the diagnosis of leishmaniasis, particularly in endemic areas.
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Review, Journal, Combination therapy: Combination Therapy for Post-Kala-Azar Dermal Leishmaniasis: A Literature Review of Current Evidence. (Pubmed Central) - Dec 9, 2024
Therefore, multicentric randomized controlled trials with a sufficiently large sample size are urgently needed to verify the efficacy, safety, and other advantages of combination therapies for PKDL. With the availability of liposomal amphotericin-B, miltefosine and immunotherapy, clinical management of PKDL appears promising.
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Journal: Characterizing Leishmania infantum-induced resistance to trivalent stibogluconate (SbIII) through deep proteomics. (Pubmed Central) - Oct 27, 2024
In this study, we aimed to investigate resistance to trivalent sodium stibogluconate in vitro using promastigotes from a wild strain of L. infantum...Results showed a complex proteomic adaptation in the resistant line, involving transcriptional and translational proteins, energy compensation, and homeostasis maintenance. These insights contribute to understanding the molecular adaptation in the parasite and provide information to new investigations related to therapeutics development.
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Journal: Cytokine profiles, blood parasite load and clinical features of visceral leishmaniasis in West Pokot County, Kenya. (Pubmed Central) - Sep 23, 2024
This study measured the serum cytokine profile, blood parasite load and clinical and haematological features of VL patients from West Pokot County, Kenya, over the course of treatment with sodium stibogluconate and paromomycin (SSG-PM)...In conclusion, the results suggest that SSG-PM treatment of VL patients from West Pokot was effective. Moreover, both inflammatory and regulatory immune responses appeared to decrease during treatment, although the increase in IL-17A could reflect a partial continuation of immune activation.
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Journal: A Case Series of 36 Patients Treated for Old World Cutaneous leishmaniasis. (Pubmed Central) - Jul 15, 2024
The cure rate of intramuscular meglumine antimoniate was higher than amphotericin B, which was higher than the cure rate of sodium stibogluconate. In patients treated with intralesional meglumine antimoniate, reducing the time interval between injections increased the clearance rate and decreased the rate of relapse.
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Journal: Amphotericin B Deoxycholate Treatment of Post-Kala-Azar Dermal Leishmaniasis in India. (Pubmed Central) - Jul 3, 2024
The late 1980s and early 1990s saw the use of sodium stibogluconate and amphotericin B (AmB) for a brief period...A 30-infusion regimen of AmB remains highly effective in PKDL. Without a shorter, safer, and more economical regimen for the treatment of PKDL, it should be used until a better regimen is available.
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Review, Journal: Treatment of mucocutaneous leishmaniasis - A systematic review. (Pubmed Central) - Jun 10, 2024
Other therapeutic options include itraconazole, fluconazole, ketoconazole, aminosidine sulfate, and azithromycin. The choice of drug depends primarily on its availability in the endemic area and the patient's comorbidities.
- |||||||||| Fexinidazole Winthrop (fexinidazole) / Sanofi, Lenocta (sodium stibogluconate) / VioQuest
PK/PD data, Journal: Leishmania blood parasite dynamics during and after treatment of visceral leishmaniasis in Eastern Africa: A pharmacokinetic-pharmacodynamic model. (Pubmed Central) - May 1, 2024
This BLI approach also enables an in-depth pharmacodynamic comparison between novel drug leads and may constitute an essential tool for the design of potential drug combinations. This semi-mechanistic pharmacokinetic-pharmacodynamic model adequately captured the blood parasite dynamics during and after treatment, and revealed that high blood parasite loads on Day 28 and Day 56 after start of treatment are an early indication for VL relapse, which could be a useful biomarker to assess treatment efficacy of a treatment regimen in a clinical trial setting.
- |||||||||| LXE408 / Novartis
Enrollment open, Trial primary completion date: LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study (clinicaltrials.gov) - Apr 8, 2024
P2, N=52, Recruiting,
VL-HLH is milder than EBV-HLH, with less severe liver injury and inflammatory responses, and timely treatment with antileishmanial agents is essential to improve the outcomes of pediatric patients with VL-HLH. Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2025 --> Jun 2025
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Journal, Immune cell: Effect of sodium stibogluconate in recruiting and awakening immune cells in the pleural fluid of pancreatic cancer: preparation for immunotherapy. (Pubmed Central) - Feb 9, 2024
Our study showed that the process of SSG fusion treatment of ascites and pleural effusion, the interaction between TandNK cells, MPs cells, monocytes and neutrophils was induced, and large numbers of genes were expressed, resulting in upregulation of immune response, which also approved that SSG is not only used as a protein tyrosine phosphatase inhibitor, but also it works as a protein tyrosine phosphatase inhibitor. It can also be used to regulate immune cell function, recruiting immune cells to the right place with the help of PD-1 or PD-L1 to fight cancer cells in ascites and pleural effusions in cancer patients.
- |||||||||| LXE408 / Novartis
Trial completion date, Trial initiation date, Trial primary completion date: LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study (clinicaltrials.gov) - Nov 21, 2023
P2, N=52, Not yet recruiting,
It can also be used to regulate immune cell function, recruiting immune cells to the right place with the help of PD-1 or PD-L1 to fight cancer cells in ascites and pleural effusions in cancer patients. Trial completion date: Jan 2025 --> Jul 2025 | Initiation date: Sep 2023 --> Jan 2024 | Trial primary completion date: Jan 2025 --> Jul 2025
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest, AiRuiKa (camrelizumab) / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker: Anti-PD-1 treatment protects against seizure by suppressing sodium channel function. (Pubmed Central) - Oct 31, 2023
Trial completion date: Jan 2025 --> Jul 2025 | Initiation date: Sep 2023 --> Jan 2024 | Trial primary completion date: Jan 2025 --> Jul 2025 Our study reveals that neuronal PD-1 plays an important role in epilepsy and that anti-PD-1 treatment protects against seizures by suppressing sodium channel function, identifying anti-PD-1 treatment as a novel therapeutic strategy for epilepsy.
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Journal: Histological findings associated with treatment response in cutaneous leishmaniasis: a clinicopathological correlation study. (Pubmed Central) - Sep 23, 2023
Our study reveals that neuronal PD-1 plays an important role in epilepsy and that anti-PD-1 treatment protects against seizures by suppressing sodium channel function, identifying anti-PD-1 treatment as a novel therapeutic strategy for epilepsy. Histology findings proved to be better prognostic markers than clinical features for delayed responders to treatment and will aid in targeted patient management when tissue biopsies are performed in the initial diagnosis of CL.
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Journal: A case report of an uncommon presentation of cutaneous leishmaniasis: A nose lesion. (Pubmed Central) - Aug 31, 2023
The patient received daily intravenous sodium stibogluconate doses of 9 mg/kg for 20 days, and three weeks later, there was a significant clinical improvement, with the ulcer beginning to heal and no more amastigotes visible on microscopic examination. It is crucial to keep cutaneous leishmaniasis in mind as a possible diagnosis for patients with skin lesions, even in regions where the condition is not prevalent.
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Diagnostic impasse of cutaneous leishmaniasis solved by a therapeutic trial of intralesional sodium stibogluconate. () - Jul 3, 2023 - Abstract #WCD2023WCD_7453;
KEY MESSAGE The sensitivity of various laboratory methods to diagnose CL ranges from 50.68% for culture to 93.61% for PCR and 74.4% for conventional microscopy. In the event of failure to confirm a diagnosis in laboratory, it is imperative to take cognizance of the clinical morphology i.e. non-healing, indurated plaques with central ulceration and red raised margins on exposed areas and residence of the patient
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Journal: Hematological and Clinical Features Associated with Initial Poor Treatment Outcomes in Visceral Leishmaniasis Patients with and without HIV Coinfection in Gondar, Northwest Ethiopia. (Pubmed Central) - Jan 21, 2023
In this regard, particular attention to the management of superimposed disease conditions at admission, including sepsis, HIV, and dyspnea, is needed to improve VL patients' treatment outcomes. The inadequacy of the current treatments, i.e., AmBisome and miltefosine combination therapy, for HIV coinfected visceral leishmaniasis patients requires further attention as it calls for new treatment modalities.
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Preclinical, Journal: Human Lung Cancer (A549) Cell Line Cytotoxicity and Anti-Leishmania major Activity of Carissa macrocarpa Leaves: A Study Supported by UPLC-ESI-MS/MS Metabolites Profiling and Molecular Docking. (Pubmed Central) - Dec 24, 2022
The MeOH fraction exhibited higher cytotoxic activity (IC 1.57 ± 0.04 μg/mL) than the standard drug, etoposide (IC 50.8 ± 3.16 μg/mL)...major results revealed strong growth inhibitory effects of the EtOAc fraction against L. major promastigotes (IC 27.52 ± 0.7 μg/mL) and axenic amastigotes (29.33 ± 4.86% growth inhibition at 100 μg/mL), while the butanol fraction exerted moderate activity against promastigotes (IC 73.17 ± 1.62), as compared with miltefosine against promastigotes (IC 6.39 ± 0.29 μg/mL) and sodium stibogluconate against axenic amastigotes (IC 22.45 ± 2.22 μg/mL)...These results are promising and encourage the pursuit of preclinical research using C. macrocarpa's MeOH fraction as anti-lung cancer and the EtOAc fraction as an anti-L. major drug candidates.
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Leishmaniasis: disease pattern and response to treatment in children (Convention Center - Hall 4A (4th Floor); In-Person-Only) - Oct 9, 2022 - Abstract #ASTMH2022ASTMH_1748;
Majority (63.6%) failed to respond to standard weekly intra-lesional sodium stibogluconate (IL-SSG) after 10 weeks of follow up...High proportion of IL-SSG-failures warrants review of therapeutic protocols. The apparent low case numbers reported in younger age groups, raise concerns of possible underreporting and undiagnosed patients among children, especially boys, which may add to the disease reservoir pool thus contributing to disease spread, hence of potential public health significance.
- |||||||||| Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Lenocta (sodium stibogluconate) / VioQuest
Clinical, Journal: Evaluating the Efficacy of Combined Intralesional Sodium Stibogluconate Plus Topical Imiquimod on Healing and Risk of Scarring of Cutaneous Leishmaniasis: A Case-Control Study. (Pubmed Central) - Sep 29, 2022
The apparent low case numbers reported in younger age groups, raise concerns of possible underreporting and undiagnosed patients among children, especially boys, which may add to the disease reservoir pool thus contributing to disease spread, hence of potential public health significance. Combined intralesional SSG plus topical imiquimod was beneficial in accelerating CL healing and improving scar quality, and should be considered when CL is located in aesthetically sensitive areas.
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Biomarker, Review, Journal: Global distribution of treatment resistance gene markers for leishmaniasis. (Pubmed Central) - Aug 25, 2022
Due to the emergence of resistant genes mainly in anthroponotic Leishmania species such as L. donovani and L. tropica, as the causative agents of ACL and AVL, respectively, selection of an appropriate treatment modality is essential. Physicians should be aware of the presence of such resistance for the selection of proper treatment modalities in endemic countries.
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Journal: Epidemiology and clinical features of cutaneous leishmaniasis in Khyber Pakhtunkhwa, Pakistan. (Pubmed Central) - Aug 12, 2022
Upon treatment by Sodium stibogluconate (SSG) 97% (n=362) showed clinical signs of complete or partial recovery of their skin lesions. Conclusively, highest incidence of leishmania infection occurred during short study period and majority of the cases showed positive response to treatment.
- |||||||||| Lenocta (sodium stibogluconate) / VioQuest
Journal: Unique thiol metabolism in trypanosomatids: Redox homeostasis and drug resistance. (Pubmed Central) - Jul 26, 2022
These molecules accept electrons from the reduced trypanothione and donate their electrons to other proteins, and these proteins reduce toxic molecules, neutralize reactive oxygen, or nitrogen species; and help parasites to cope with oxidative stress. Thus, a better understanding of the role of these molecules in drug resistance and redox homeostasis will help to target metabolic pathway proteins to combat Leishmaniasis and trypanosomiases.
|
